Sea ice decline drives biogeographical shifts of key Calanus species in the central Arctic Ocean.

In recent decades, the central Arctic Ocean has been experiencing dramatic decline in sea ice coverage, thickness and extent, which is expected to have a tremendous impact on all levels of Arctic marine life. Here, we analyze the regional and temporal changes in pan-Arctic distribution and population structure of the key zooplankton species Calanus glacialis and C. hyperboreus in relation to recent changes in ice conditions, based on historical (1993-1998) and recent (2007-2016) zooplankton collections and satellite-based sea ice observations.

Diagnosis and Empirical Treatment of Urinary Tract Infections in Urologic Outpatients.

Introduction: Due to a continuing increase of bacterial resistance in common uropathogens, we wanted to revisit our standards for the diagnosis and treatment of lower urinary tract infections, in the setting of urological outpatient care in a conurbation in Germany.

Patients And Methods: All subjects presenting with significant bacteriuria at our urology clinics in Mülheim, Germany, in 2011 were included. Comorbidity, bacterial species, urinary tract symptoms, and empirically prescribed antibiotics were taken from the patients' records.

Visual rehabilitation of patients with corneal diseases.

Background: Although most patients with visual impairment due to corneal diseases can be treated successfully with surgery, some require visual rehabilitation to restore reading ability. To evaluate the best LVAs especially in terms of reading speed and characterize this specific patient group we performed a prospective, randomized cross-over trial.

Methods: All 34 patients underwent a detailed examination (slit-lamp, funduscopy, SD-OCT, ETDRS) as screening.

Fallacies of clinical studies on folic acid hazards in subjects with a low vitamin B status.

A 2016 plea for revision of the 1 mg/day upper level of folic acid intake prompted us to comprehensively review the 1945-2017 literature on folic acid hazards in subjects with low cyanocobalamin. The concept of folic acid treatment 'masking' the anemia in undiagnosed cyanocobalamin deficiency, thereby delaying the diagnosis of neuropathy, does not account for the dissociation between the deficiency's hematologic and neurologic manifestations. Possible risks of this concept were addressed by 1963-1971 FDA rulings, classifying all folic acid preparations as prescription-only drugs, delivering ≤1 mg daily.

Folic acid and primary prevention of neural tube defects: A review.

With 4 mg folic acid daily, it may take 20 weeks to reach red-blood-cell folate levels between 1050 and 1340 nmol/L, optimal for reduction of the neural tube defect risk. Therefore, folic acid supplementation should be started 5-6 months before conception. The residual risk with optimal red-blood-cell folate levels is reportedly 4.